iShares Biotechnology ETF
428 hedge funds and large institutions have $3.72B invested in iShares Biotechnology ETF in 2016 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 149 increasing their positions, 122 reducing their positions, and 52 closing their positions.
37% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 52
22% more repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 122
3% more funds holding
Funds holding: 414 → 428 (+14)
4% less capital invested
Capital invested by funds: $3.86B → $3.72B (-$137M)
5% less funds holding in top 10
Funds holding in top 10: 21 → 20 (-1)
55% less call options, than puts
Call options by funds: $629M | Put options by funds: $1.39B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$136M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$136M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$83.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$52.9M |
| 5 |
SG Americas Securities
New York
|
+$47.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$164M |
| 2 |
Morgan Stanley
New York
|
-$148M |
| 3 |
Goldman Sachs
New York
|
-$134M |
| 4 |
Jane Street
New York
|
-$72.2M |
| 5 |
LPL Financial
San Diego,
California
|
-$71.8M |
IBB Hedge Fund Activity: Q2 2016 in Review
428 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2016, worth a combined $3.72B — down 3.6% from $3.86B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new IBB positions and 52 closed out — a net gain of 19 holders — while 149 added to existing stakes and 122 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $136M. The largest seller was Citigroup, cutting an estimated $164M.
- 428 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2016, up from 414 in Q1 2016.
- Funds reported $3.72B of iShares Biotechnology ETF stock for Q2 2016, down 3.6% quarter-over-quarter.
- 71 funds opened new iShares Biotechnology ETF positions in Q2 2016 and 52 closed out, a net change of +19 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2016 was JP Morgan Chase, an estimated $136M added.
- The largest iShares Biotechnology ETF seller in Q2 2016 was Citigroup, an estimated $164M sold.
Based on aggregated 13F filings for Q2 2016.